Pfizer and BioNTech prepare to expand COVID-19 vaccine trial

By Rachel Arthur contact

- Last updated on GMT

Pfizer says its COVID-19 vaccine trial is running to schedule. Pic:getty/bojan89
Pfizer says its COVID-19 vaccine trial is running to schedule. Pic:getty/bojan89

Related tags: Pfizer, BioNTech, COVID-19 vaccine

Pfizer and BioNTech plan to expand the enrolment of their Phase 3 pivotal COVID-19 vaccine trial to up to 44,000 participants: which will also include new populations.

The proposed expansion will allow the companies to diversify their mRNA vaccine candidate trial further: including people aged from 16-years old (down from the current limit of 18 years old); and people with chronic, stable HIV; Hepatitis C or Hepatitis B infection. The trial will also provide additional safety and efficacy data.

Pfizer and BioNTech announced Saturday they have submitted an amended protocol to the U.S. Food and Drug Administration (FDA) for the expanded trial.

Trials 'proceeding as planned' 

Germany’s BioNTech and US-based Pfizer are developing a nucleoside-modified messenger RNA vaccine candidate.

Enrolment in clinical trials is ‘proceeding as planned’ and the companies expect to reach the initial target of 30,000 participants over the coming week.

“The pivotal trial is event-based and there are many variables that will ultimately impact read-out timing,” ​said Pfizer and BioNTech in a statement on Saturday. “As stated previously, based on current infection rates, the companies continue to expect that a conclusive readout on efficacy is likely by the end of October.

Related topics: Bio Developments

Related news

Show more

Follow us

Products

View more

Webinars